To be realistic I'm not expecting NPAT 15% for the next 1-2 years, as the ship is just turning.
Sustainable Revenue growth is the most significant sign of positive, outlook suggest FY25 will way overpass the $400-450m revenue mark, as revenue increase the Direct Opex will be substantially lower and the margin will rise further.
Also the 2nd half net loss includes the $33m settlement payout and the Earn-out payment, so the real loss is much lower.
When approach NPAT break-even the ratio of less than 1 ( revenum $400-450m vs MC $370)will be screamingly cheap.
- Forums
- ASX - By Stock
- What MYX chart shouts
MYX
mayne pharma group limited
Add to My Watchlist
2.30%
!
$5.34

To be realistic I'm not expecting NPAT 15% for the next 1-2...
Featured News
Add to My Watchlist
What is My Watchlist?
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
|
|||||
Last
$5.34 |
Change
0.120(2.30%) |
Mkt cap ! $433.8M |
Open | High | Low | Value | Volume |
$5.29 | $5.34 | $5.15 | $705.4K | 133.2K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
2 | 2000 | $5.31 |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
$5.34 | 3653 | 3 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
2 | 2000 | 5.310 |
1 | 864 | 5.290 |
1 | 28009 | 5.280 |
2 | 2631 | 5.250 |
1 | 402 | 5.240 |
Price($) | Vol. | No. |
---|---|---|
5.340 | 3653 | 3 |
5.350 | 16680 | 3 |
5.370 | 1631 | 1 |
5.390 | 1631 | 1 |
5.400 | 26805 | 3 |
Last trade - 16.10pm 18/06/2025 (20 minute delay) ? |
Featured News
MYX (ASX) Chart |
The Watchlist
MEM
MEMPHASYS LIMITED.
Professor John Aitken, Scientific Director
Professor John Aitken
Scientific Director
Previous Video
Next Video
SPONSORED BY The Market Online